Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

  title={Congestive heart failure risk in patients with breast cancer treated with bevacizumab.},
  author={Toni K Choueiri and Erica L Mayer and Youjin Je and Jonathan E Rosenberg and Paul Linh Nguyen and Georges R Azzi and Joaquim Bellmunt and Harold J. Burstein and Fabio Augusto Barros Schutz},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  volume={29 6},
PURPOSE Bevacizumab is a treatment option in patients with metastatic breast cancer. Congestive heart failure (CHF) has been reported, although the overall incidence and relative risk (RR) of this complication remains unclear. We performed an up-to-date, comprehensive meta-analysis to determine the risk of serious CHF in patients with breast cancer receiving bevacizumab. METHODS The databases of Medline were searched for articles from 1966 to March 2010. Abstracts presented at the American… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
99 Citations
30 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 99 extracted citations


Publications referenced by this paper.
Showing 1-10 of 30 references

Cardiovascular safety of adjuvant bevacizumab for breast cancer

  • EL Mayer, A Nohria, K Miller
  • J Clin Oncol (Meeting Abstracts)
  • 2010
1 Excerpt

Multinational study (n 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): u{Updated results of MO19391

  • H Cortes-Funes, KI Pritchard, L Biganzoli
  • Eur Cancer Suppl 7:265, 2009
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…